[{"indications": "Indications\u00a0\n(From 8.1.4 Vinca alkaloids and etoposide: British National Formulary)\nEtoposide may be given orally or by slow intravenous infusion, the oral dose being double the intravenous dose. A preparation containing etoposide phosphate can be given by intravenous injection or infusion. Etoposide is usually given daily for 3\u20135 days and courses should not be repeated more frequently than at intervals of 21 days. It has particularly useful activity in small cell carcinoma of the bronchus, the lymphomas, and testicular cancer.", "name": "ETOPOSIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "8 Malignant disease and immunosuppression", "8.1 Cytotoxic drugs", "8.1.4 Vinca alkaloids and etoposide", "ETOPOSIDE"], "cautions": "Cautions\u00a0see section 8.1 and notes above; interactions: Appendix 1 (etoposide)", "side-effects": "Side-effects\u00a0see section 8.1; irritant to tissues", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/4749.htm", "doses": ["By mouth, 120\u2013240\u00a0mg/m2 daily\r\nfor 5 days", "By intravenous infusion, consult product literature"], "pregnancy": "Pregnancy\u00a0avoid (teratogenic in animal studies);\r\nsee also Pregnancy and Reproductive\r\nFunction"}]